Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts at ESMO 2024 Annual Meeting.

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts at ESMO 2024 Annual Meeting.

BARCELONA, Spain, September 20, 2024 /PRNewswire/ — Highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress took place from September 13 to 17 to Barcelona, ​​Spain. As one …

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts at ESMO 2024 Annual Meeting. Read More